CoChat

Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology

Open access
On behalf of the EUROASPIRE Investigators, Gyberg, Viveca, De Bacquer, Dirk, De Backer, Guy, Jennings, Catriona, Kotseva, Kornelia, Mellbin, Linda, Schnell, Oliver, Tuomilehto, Jaakko, Wood, David, Rydén, Lars, Amouyel, Philippe, Bruthans, Jan, Conde, Almudena Castro, Cifkova, Renata, Deckers, Jaap W., De Sutter, Johan, Dilic, Mirza, Dolzhenko, Maryna, Erglis, Andrejs, Fras, Zlatko, Gaita, Dan, Gotcheva, Nina, Goudevenos, John, Heuschmann, Peter, Laucevicius, Aleksandras, Lehto, Seppo, Lovic, Dragan, Miličić, Davor, Moore, David, Nicolaides, Evagoras, Oganov, Raphael, Pająk, Andrzej, Pogosova, Nana, Reiner, Zeljko, Stagmo, Martin, Störk, Stefan, Tokgözoğlu, Lale, Vulic, Dusko · 2015 · Cardiovascular Diabetology

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

BACKGROUND: In order to influence every day clinical practice professional organisations issue management guidelines. Cross-sectional surveys are used to evaluate the implementation of such guidelines. The present survey investigated screening for glucose perturbations in people with coronary artery disease and compared patients with known and newly detected type 2 diabetes with those without diabetes in terms of their life-style and pharmacological risk factor management in relation to contemporary European guidelines. METHODS: A total of 6187 patients (18-80 years) with coronary artery disease and known glycaemic status based on a self reported history of diabetes (previously known diabetes) or the results of an oral glucose tolerance test and HbA1c (no diabetes or newly diagnosed diabetes) were investigated in EUROASPIRE IV including patients in 24 European countries 2012-2013. The patients were interviewed and investigated in order to enable a comparison between their actual risk factor control with that recommended in current European management guidelines and the outcome in previously conducted surveys. RESULTS: A total of 2846 (46%) patients had no diabetes, 1158 (19%) newly diagnosed diabetes and 2183 (35%) previously known diabetes. The combined use of all four cardioprotective drugs in these groups was 53, 55 and 60%, respectively. A blood pressure target of <140/90 mmHg was achieved in 68, 61, 54% and a LDL-cholesterol target of <1.8 mmol/L in 16, 18 and 28%. Patients with newly diagnosed and previously known diabetes reached an HbA1c <7.0% (53 mmol/mol) in 95 and 53% and 11% of those with previously known diabetes had an HbA1c >9.0% (>75 mmol/mol). Of the patients with diabetes 69% reported on low physical activity. The proportion of patients participating in cardiac rehabilitation programmes was low (≈40 %) and only 27% of those with diabetes had attended diabetes schools. Compared with data from previous surveys the use of cardioprotective drugs had increased and more patients were achieving the risk factor treatment targets. CONCLUSIONS: Despite advances in patient management there is further potential to improve both the detection and management of patients with diabetes and coronary artery disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-015-0296-y

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Proportion of patients with no, newly diagnosed and known diabetes prescribed the different cardioprotective drugs alone and in combination. Renin–angiotensin–aldosterone–system (RAAS)-blockers includes angiotensin converting enzyme inhibitors and angiotensin receptor blockers. ASA aspirin. All 4 = the combination of aspirin (or other anticoagulants) + a β-blocker + a RAAS-blocker and a statin. *p < 0.0001
Fig. 1 Proportion of patients with no, newly diagnosed and known diabetes prescribed the different cardioprotective drugs alone and in combination. Renin–angiotensin–aldosterone–system (RAAS)-blockers includes angiotensin converting enzyme inhibitors and angiotensin receptor blockers. ASA aspirin. All 4 = the combination of aspirin (or other anticoagulants) + a β-blocker + a RAAS-blocker and a statin. *p < 0.0001CC BY · PubMed Central
Fig. 2 a Proportion of patients with no, newly diagnosed and known diabetes reaching different blood pressure targets. b Proportion of patients with no, newly diagnosed and known diabetes reaching different LDL-cholesterol targets.
Fig. 2 a Proportion of patients with no, newly diagnosed and known diabetes reaching different blood pressure targets. b Proportion of patients with no, newly diagnosed and known diabetes reaching different LDL-cholesterol targets.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 140

Metadata

Authors
On behalf of the EUROASPIRE Investigators, Gyberg, V., De Bacquer, D., De Backer, G., Jennings, C., Kotseva, K., Mellbin, L., Schnell, O., Tuomilehto, J., Wood, D., Rydén, L., Amouyel, P., Bruthans, J., Conde, A. C., Cifkova, R., Deckers, J. W., De Sutter, J., Dilic, M., Dolzhenko, M., Erglis, A., Fras, Z., Gaita, D., Gotcheva, N., Goudevenos, J., Heuschmann, P., Laucevicius, A., Lehto, S., Lovic, D., Miličić, D., Moore, D., Nicolaides, E., Oganov, R., Pająk, A., Pogosova, N., Reiner, Z., Stagmo, M., Störk, S., Tokgözoğlu, L., & Vulic, D.
Affiliations
  • Karolinska University Hospital (SE)
  • European Society of Cardiology (FR)
  • Universität für Weiterbildung Krems (AT)
  • Inserm (FR)
  • Charles University (CZ)
  • Erasmus MC (NL)
  • University of Ljubljana (SI)
  • University of Ioannina (GR)
  • Vilnius University (LT)
  • University of Nicosia (CY)
  • University of Würzburg (DE)
Corresponding author
Rydén, Lars
Venue
Cardiovascular Diabetology
Published
2015-10-01
Volume
14
Issue
1
Pages
133-133
ISSN
1475-2840 (ISSN-L)
OpenAlex
W2137605883
Cited by
140
References
42
Citations by year
2026: 2 · 2025: 10 · 2024: 17 · 2023: 11 · 2022: 19 · 2021: 13 · 2020: 15 · 2019: 15 · 2018: 9 · 2017: 14 · 2016: 14 · 2015: 1
FWCI
11.01
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Dr Med - University of Zagreb School of Medicine Digital Repository (acceptedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (acceptedVersion, other-oa)
  • Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
  • Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
  • Lund University Publications (Lund University) (submittedVersion, other-oa)
  • Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
  • Online Publication Service of Würzburg University (Würzburg University) (submittedVersion, cc-by)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
  • STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
  • WOS
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • AstraZeneca
  • Bayer
  • GlaxoSmithKline
  • Sanofi
  • F. Hoffmann-La Roche
  • Kowa Company
  • National Institute for Health and Care Research (NF-SI-0508-10312)
  • European Society of Cardiology
  • Bundesministerium für Bildung und Forschung (01EO1004, BMBF01EO1004)
  • Hjärt-Lungfonden
  • Novo Nordisk
  • Servier
  • Merck Sharp and Dohme
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
coronary artery disease, type 2 diabetes, newly diagnosed diabetes, risk factor control, guideline implementation, HbA1c, blood pressure control, LDL cholesterol, cardioprotective drugs, physical activity, cardiac rehabilitation, diabetes education, EUROASPIRE IV, cardiovascular risk stratification, lifestyle management, glucose screening, HbA1c screening, oral glucose tolerance test
MeSH terms
Adrenergic beta-Antagonists, Aged, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Blood Pressure, Cardiotonic Agents, Coronary Artery Disease, Cross-Sectional Studies, Diabetes Mellitus, Type 2, Europe, Female, Humans, Hypertension, Hypoglycemic Agents, Cholesterol, LDL, Male, Middle Aged, Platelet Aggregation Inhibitors, Registries, Risk Factors, Practice Guidelines as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Guideline Adherence, Dyslipidemias, Secondary Prevention, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. https://app.cochat.ai/papers/10.1186/s12933-015-0296-y
The paper
On behalf of the EUROASPIRE Investigators, Gyberg, V., De Bacquer, D., De Backer, G., Jennings, C., Kotseva, K., Mellbin, L., Schnell, O., Tuomilehto, J., Wood, D., Rydén, L., Amouyel, P., Bruthans, J., Conde, A. C., Cifkova, R., Deckers, J. W., De Sutter, J., Dilic, M., Dolzhenko, M., . . . Vulic, D. (2015). Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-015-0296-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.